Jade Biosciences, Inc. Foreign Income Tax Expense (Benefit), Continuing Operations
Jade Biosciences, Inc. (JBIO) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $100.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-08-10
- Jade Biosciences, Inc. foreign income tax expense (benefit), continuing operations for the quarter ending 2026-06-30 was $0.00.
- Jade Biosciences, Inc. foreign income tax expense (benefit), continuing operations for the quarter ending 2026-03-31 was $100.00K.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 3 month | Foreign Income Tax Expense (Benefit), Continuing Operations 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $100.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |